Pfizer and Astellas Pharma Inc announced results from their joint Phase 3 ARCHES trial in men with metastatic hormone-sensitive prostate cancer (mHSPC). The results evidence that XTANDI® (enzalutamide) plus androgen deprivation therapy (ADT) met the primary endpoint by significantly reducing the risk of radiographic progression or death by 61% vs. ADT alone (n=1,150; HR=0.39 [95% CI: 0.30-0.50]; p<0.0001).As reported in Street Insider, this report “The ARCHES trial demonstrated that XTANDI plus standard hormonal therapy delayed disease progression, and if approved, has the potential to be an important treatment option for men with prostate cancer that has spread but has not yet become hormone resistant,” said Andrew Armstrong, M.D., Professor of Medicine, Surgery, Pharmacology and Cancer Biology, and Director of Research in the Duke Cancer Institute’s Center for Prostate and Urologic Cancers.

Source: Street Insider

Pin It on Pinterest